Insulet (PODD) Cash from Investing Activities (2010 - 2026)

Insulet (PODD) posted Cash from Investing Activities of -$27.7 million for Q1 2026, up 81.87% on a QoQ basis from -$152.8 million in Q4 2025, and down 77.56% year-over-year from -$123.5 million in Q1 2025.

Insulet (PODD) Cash from Investing Activities (2010 - 2026) Analysis & Trends

Insulet's Cash from Investing Activities history runs 17 years deep, the most recent figure standing at -$27.7 million for Q1 2026.

  • Quarterly Cash from Investing Activities fell 77.56% year-over-year to -$27.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$234.8 million (down 70.39% YoY) and the FY2025 annual result came in at -$222.7 million, down 52.33% from the prior year.
  • Cash from Investing Activities was -$27.7 million for Q1 2026 at Insulet, up from -$152.8 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at -$15.6 million in Q1 2025 and bottomed at -$152.8 million in Q4 2025.
  • A 5-year average of -$41.6 million and a median of -$29.3 million in 2024 frame the typical range for Cash from Investing Activities.
  • Annual changes were most pronounced in 2022 — Cash from Investing Activities sank 177.87% — and 2023, when it soared 64.25%.
  • Insulet's Cash from Investing Activities stood at -$88.4 million in 2022, then surged by 64.25% to -$31.6 million in 2023, then tumbled by 115.19% to -$68.0 million in 2024, then plunged by 124.71% to -$152.8 million in 2025, then surged by 81.87% to -$27.7 million in 2026.
  • Business Quant data shows PODD's Cash from Investing Activities at -$27.7 million in Q1 2026, -$152.8 million in Q4 2025, and -$31.0 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Abbott Laboratories 182.32 Bn 175.02 Bn 6.27 Bn -20.32 Bn
2 Stryker 128.75 Bn 125.88 Bn 3.81 Bn -185.00 Mn
3 Medtronic 107.83 Bn 98.61 Bn 6.41 Bn -917.00 Mn
4 Boston Scientific 67.61 Bn 66.15 Bn 3.61 Bn -591.00 Mn
5 Edwards Lifesciences 48.13 Bn 44.45 Bn 1.29 Bn -92.80 Mn
6 Dexcom 28.26 Bn 27.14 Bn 750.30 Mn -298.50 Mn
7 GE HealthCare Technologies 27.78 Bn 25.50 Bn 1.98 Bn -2.50 Bn
8 Smith & Nephew 26.99 Bn 26.41 Bn - -
9 Koninklijke Philips 23.92 Bn 20.80 Bn 2.07 Bn -475.32 Mn
10 Insulet 11.52 Bn 11.04 Bn 529.10 Mn -27.70 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -27.70 Mn
Mar 31, 2026 -27.70 Mn
Dec 31, 2025 -152.80 Mn
Dec 31, 2025 -152.80 Mn
Sep 30, 2025 -31.00 Mn
Sep 30, 2025 -31.00 Mn
Jun 30, 2025 -23.30 Mn
Jun 30, 2025 -23.30 Mn
Mar 31, 2025 -15.60 Mn
Mar 31, 2025 -15.60 Mn
Dec 31, 2024 -68.00 Mn
Dec 31, 2024 -68.00 Mn
Sep 30, 2024 -29.30 Mn
Sep 30, 2024 -29.30 Mn
Jun 30, 2024 -24.90 Mn
Jun 30, 2024 -24.90 Mn
Mar 31, 2024 -24.00 Mn
Mar 31, 2024 -24.00 Mn
Dec 31, 2023 -31.60 Mn
Dec 31, 2023 -31.60 Mn